SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAGANELLI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.884
EU - Europa 2.820
AS - Asia 1.873
SA - Sud America 106
AF - Africa 12
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.706
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.859
PL - Polonia 1.263
CN - Cina 735
SG - Singapore 530
IT - Italia 366
TR - Turchia 323
UA - Ucraina 276
SE - Svezia 252
DE - Germania 235
GB - Regno Unito 209
ID - Indonesia 99
BR - Brasile 91
VN - Vietnam 82
IE - Irlanda 48
NL - Olanda 27
RU - Federazione Russa 26
BE - Belgio 22
JO - Giordania 21
FR - Francia 20
KR - Corea 20
CA - Canada 19
FI - Finlandia 14
RO - Romania 14
HK - Hong Kong 13
IN - India 13
AU - Australia 8
PT - Portogallo 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
CZ - Repubblica Ceca 6
GR - Grecia 5
JP - Giappone 5
BG - Bulgaria 4
AR - Argentina 3
BD - Bangladesh 3
BO - Bolivia 3
CH - Svizzera 3
CO - Colombia 3
DK - Danimarca 3
IQ - Iraq 3
IR - Iran 3
LT - Lituania 3
MX - Messico 3
MY - Malesia 3
PE - Perù 3
SC - Seychelles 3
ZA - Sudafrica 3
AL - Albania 2
CY - Cipro 2
EU - Europa 2
MA - Marocco 2
PH - Filippine 2
PK - Pakistan 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
DZ - Algeria 1
EC - Ecuador 1
ES - Italia 1
GA - Gabon 1
GE - Georgia 1
GL - Groenlandia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
MK - Macedonia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
PA - Panama 1
PY - Paraguay 1
SV - El Salvador 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 14.706
Salva come PNG Salva come JPEG
Città #
Fairfield 1.499
Warsaw 1.259
Woodbridge 1.181
Ashburn 826
Houston 752
Seattle 605
Chandler 551
Santa Clara 536
Jacksonville 495
Wilmington 495
Cambridge 486
Ann Arbor 380
Singapore 346
Izmir 297
Princeton 183
Nanjing 170
Milan 122
San Diego 106
Beijing 101
Boardman 101
Jakarta 97
Dearborn 94
Dong Ket 82
Menlo Park 69
Nanchang 67
Ferrara 52
London 48
Los Angeles 47
Hebei 45
Falls Church 42
Shenyang 38
Bologna 32
Mountain View 30
Tianjin 29
Shanghai 28
Changsha 25
Jiaxing 25
Kunming 24
Redwood City 24
Washington 23
Brussels 22
Norwalk 22
Orange 19
Scottsdale 16
Jinan 15
Fuzhou 14
Addison 13
Rome 13
Seongnam 13
Helsinki 12
New York 12
Bremen 11
Zhengzhou 11
Tappahannock 10
Toronto 10
Guangzhou 9
Hong Kong 9
Indiana 9
Phoenix 9
Chicago 8
Hefei 8
Hounslow 8
Kilburn 8
Poggio Renatico 8
Frankfurt am Main 7
Lanzhou 7
Simi Valley 7
São Paulo 7
Belo Horizonte 6
Cesena 6
Changchun 6
Dublin 6
Forlimpopoli 6
Putian 6
Redmond 6
Seoul 6
Walnut 6
Castenaso 5
Edinburgh 5
Pune 5
San Mateo 5
Vienna 5
Amsterdam 4
Council Bluffs 4
Hangzhou 4
Ilmenau 4
Monmouth Junction 4
Rio De Janeiro 4
Tokyo 4
Chengdu 3
La Paz 3
Lelystad 3
Lima 3
Lisbon 3
Mcallen 3
Mulhouse 3
North Bergen 3
Ottawa 3
Philadelphia 3
Piscataway 3
Totale 11.869
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 370
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 292
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 218
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 214
Development of sentinel node localization and ROLL in breast cancer in Europe 210
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 205
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 196
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 196
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 182
Early use of abiraterone and radium-223 in metastatic prostate cancer 172
A novel radioguided surgery technique exploiting β- decays 170
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 169
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 161
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 160
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 159
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 150
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 138
Radioimmunotherapy in brain tumors 137
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 131
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 130
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 130
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 128
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 126
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 125
A parathyroid carcinoma within a cold thyroid nodule 120
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 119
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 113
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 111
Yttrium-labelled peptides for therapy of NET 110
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 109
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 108
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 107
Long-term results of PRRT in advanced bronchopulmonary carcinoid 106
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 106
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 105
Sentinel lymph node biopsy in pregnant patients with breast cancer 105
Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening 104
Neuroendocrine tumors 104
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 104
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 103
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 103
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 102
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 101
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 101
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 101
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 101
OXavidin for tissue targeting biotinylated therapeutics 100
Yttrium-based therapy for neuroendocrine tumors 100
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 100
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 100
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 99
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 99
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 98
Hibernoma mimicking metastasis on positron emission tomography-computed tomography imaging: A misleading finding in oncologic patient follow-up 98
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 97
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 97
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 96
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 96
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 95
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 95
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 95
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 94
PET imaging of HER-2-positive tumours 94
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 94
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 94
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 94
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 94
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans 93
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 92
Preoperative FDG PET/CT in breast cancer patients: Where are we going? 92
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 92
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 92
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 91
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 91
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 91
Hematologic toxicity and double autografting of stem cells after myeloablative activities of Yttrium-90-Ibritumomab tiuxetan 91
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL) 90
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 90
PET/CT and breast cancer subtypes 90
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy 89
Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas 89
Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 88
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 88
An unusual breast lesion: The ultrasonographic, mammographic, MRI and nuclear medicine findings of mammary hibernoma 87
Nonpalpable breast carcinomas: Long-term evaluation of 1,258 cases 87
Detection of a cardiac mass by [18F]FDG-PET/CT: A rare case 87
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 87
Financial aspects of sentinel lymph node biopsy in early breast cancer 86
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 86
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 86
Peptide Receptor Radionuclide Therapy (PRRT): clinical Application 84
Something more than estimating renal dosimetry 83
Computed tomography-guided preoperative radiotracer localization of nonpalpable lung nodules 83
Positron emission tomography for the detection of colorectal adenomas 83
Prostate-specific membrane antigen and renal cell carcinoma: A new diagnostic and therapeutic target? 83
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy 82
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 82
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 82
Perspectives in the development of novel treatment approaches 82
Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer 82
Totale 11.522
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.257
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.091
Totale 89.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.160 0 0 0 0 0 450 405 338 345 238 274 110
2020/20212.527 106 174 139 228 178 422 132 309 86 315 180 258
2021/20221.303 84 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/20251.497 58 97 333 157 510 342 0 0 0 0 0 0
Totale 15.241